VERTEX PHARMACEUTICALS INC / MA Deferred Tax Liabilities, Other
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Deferred Tax Liabilities, Other of $187.10 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesOther · last filed 2026-02-13
- 2025-12-31: Deferred Tax Liabilities, Other $187.10M.
- 2024-12-31: Deferred Tax Liabilities, Other $285.50M; Deferred Tax Liabilities, Other as first filed $42.00M.
- 2023-12-31: Deferred Tax Liabilities, Other $25.20M.
- 2022-12-31: Deferred Tax Liabilities, Other $27.20M.
| Period end | Deferred Tax Liabilities, Other | Deferred Tax Liabilities, Other as first filed |
|---|---|---|
| 2025-12-31 | $187.10M 10-K · filed 2026-02-13 | |
| 2024-12-31 | $285.50M 10-K · filed 2026-02-13 | $42.00M 10-K · filed 2025-02-13 |
| 2023-12-31 | $25.20M 10-K · filed 2025-02-13 | |
| 2022-12-31 | $27.20M 10-K · filed 2024-02-15 | |
| 2021-12-31 | $56.30M 10-K · filed 2023-02-10 | |
| 2020-12-31 | $32.60M 10-K · filed 2022-02-09 | $15.07M 10-K · filed 2021-02-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 | |
| 2013-12-31 | $0.00 10-K · filed 2014-02-11 | |
| 2012-12-31 | $376.00K 10-K · filed 2014-02-11 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |